期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 21, 页码 9312-9330出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm301034u
关键词
-
资金
- Fonds Unique Interministeriel (FUI) PHARMASEA project
- Association France-Alzheimer (Finistere)
- CRITT-Sante Bretagne
- Fondation Jerome Lejeune
- Anna's Angels Down Syndrome Research Foundation
- Caroline Ball Family Fund
- Canadian Institutes for Health Research [1097737]
- Canada Foundation for Innovation, Genome Canada
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Novartis Research Foundation
- Ontario Ministry of Research and Innovation
- Wellcome Trust
- Takeda
- Cancer Research UK [14532] Funding Source: researchfish
DYRKs (dual specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) are implicated in the onset and development of Alzheimer's disease and Down syndrome. The marine sponge alkaloid leucetttamine B was recently identified as an inhibitor of DYRKs/CLKs. Synthesis of analogues (leucettines) led to an optimized product, leucettine L41. Leucettines were cocrystallized with DYRK1A, DYRK2, CLK3, PIM1, and GSK-3 beta. The selectivity of L41 was studied by activity and interaction assays of recombinant kinases and affinity chromatography and competition affinity assays. These approaches revealed unexpected potential secondary targets such as CK2, SLK, and the lipid kinase PIKfyve/Vac14/Fig4. L41 displayed neuroprotective effects on glutamate-induced HT22 cell death. L41 also reduced amyloid precursor protein-induced cell death in cultured rat brain slices. The unusual multitarget selectivity of leucettines may account for their neuroprotective effects. This family of kinase inhibitors deserves further optimization as potential therapeutics against neurodegenerative diseases such as Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据